- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Direxion Daily S&P Biotech Bear 3X Shares(LABD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LABD
11/20/2026: LABD (1-star) is currently NOT-A-BUY. Pass it for now.
Direxion Daily S&P Biotech Bear 3X Shares (LABD) is a leveraged inverse ETF designed to achieve -3x the daily performance of the S&P Biotechnology Select Industry Index through swap agreements and derivatives. Its primary strength lies in providing high-liquidity, margin-free tactical bearish exposure for active day traders targeting short-term sector downturns. The primary role of the fund is short-term speculation or tactical hedging rather than long-term asset accumulation. Key risks include severe volatility decay, compounding tracking error over extended periods, and extreme vulnerability to sudden bullish sector rallies. It is best suited for experienced, risk-tolerant tactical traders who close positions daily, requiring vigilant monitoring of market momentum and sector catalysts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | Growth investors seek capital appreciation, which contradicts the short and inverse focus of this fund. |
| Momentum investor | Strong fit while signal remains positive | Momentum traders can utilize LABD to rapidly capitalize on sharp, short-term downward momentum in the biotech sector. |
| Value investor | Weak fit | Value investing focuses on fundamentals and long-term holding, whereas LABD is a short-term trading instrument. |
| Dividend/Income investor | Weak fit | LABD does not pay meaningful dividends and is built exclusively for capital movement tracking, not income. |
| Low-risk investor | Weak fit | The triple-leveraged inverse structure introduces extreme volatility and risk of rapid capital loss. |
Investor Profile
Ideal Investor Profile
Sophisticated day traders and tactical portfolio managers with a high risk tolerance who actively monitor the market and seek short-term bearish exposure to biotech.
Suitability
Strictly suited for active short-term trading and intraday strategies, entirely inappropriate for buy-and-hold or long-term investors.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The 3x daily leverage amplifies daily price swings dramatically, exposing capital to severe fluctuations. |
| Market risk | High | Adverse rallies in the biotech sector can instantly and severely erode the value of the fund. |
| Concentration | High | The fund targets a single volatile industry sector (biotechnology), heightening sensitivity to sector-specific shocks. |
| Tracking/expense | Medium / high | Compounding over periods longer than one day can cause returns to diverge significantly from -3x the index return. |
| Liquidity | Low | Underlying market liquidity is strong, though derivative execution costs can impact performance during stressed markets. |
| Business/sector quality | High | Biotech stocks are heavily influenced by binary events like FDA decisions and clinical readouts, triggering sharp index gaps. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
Extremely high historical volatility resulting from the combined effect of high-beta biotech stocks and 3x daily leverage mechanics.
Market Risk
Vulnerable to sudden upward momentum spikes in the biotech industry, which can result in rapid and substantial losses.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Derivatives | S&P Biotechnology Select Industry Index — seeks -3x daily return | 100 | This swap-based structure provides triple inverse daily exposure to the performance of the underlying biotechnology stock index. |
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type ETF | Historic Profit -46.65% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

